Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
Summary
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
Timeline
- Start
- 2011-02
- Primary completion
- 2011-08
- Completion
- 2011-08
Outcome
Met primary endpoint
registry Healthy Participants: Placebo vs Healthy Participants: LY2189265; p <0.001; Geometric least squares (LS) mean ratio 2.96 (95% CI 2.41 to 3.64) NCT01300260 ↗
registry Healthy Participants: Placebo vs Healthy Participants: LY2189265; p <0.001; Geometric least squares (LS) mean ratio 3.09 (95% CI 2.66 to 3.59) NCT01300260 ↗
registry Healthy Participants: Placebo vs Healthy Participants: LY2189265; p <0.001; Geometric least squares (LS) mean ratio 4.15 (95% CI 3.45 to 5.00) NCT01300260 ↗
registry Healthy Participants: Placebo vs Healthy Participants: LY2189265; p = 0.011; Geometric least squares (LS) mean ratio 2.04 (95% CI 1.26 to 3.31) NCT01300260 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Background | Glucagon | Peptide | 1 mg | Intravenous |
| Background | Glucose | Unknown | 0.3 g/kg | Intravenous |
| Background | Glucose | Unknown | 15 g | Intravenous |
| Background | Glucose | Unknown | 20 g | Intravenous |
| Background | Glucose | Unknown | 25 g | Intravenous |
| Background | Insulin | Protein / enzyme biologic | — | Intravenous |